Jill Howe

Ms. Howe joined Lineage as Chief Financial Officer in November 2022. Prior to joining Lineage, Ms. Howe served as Chief Financial Officer at DTx Pharma from June 2021 to July 2022. Prior to that, from January 2018 to June 2021, she was Vice President of Finance and Treasurer at Gossamer Bio, Inc. (GOSS) and served on the Board of Directors of its Irish subsidiaries. From March 2016 to December 2017, she served as Controller and Director of Finance at Amplyx Pharmaceuticals, Inc., which was subsequently acquired by Pfizer, Inc. From May 2013 to March 2016, she served as Controller and Director of Finance at Receptos, Inc. (RPCT), which was subsequently acquired by Celgene, Inc. Prior to joining Receptos, Ms. Howe worked in various accounting roles from 2006 to 2013 leading up to Director of Finance at Somaxon Pharmaceuticals, Inc. (SOMX), which was acquired by Pernix. Ms. Howe currently serves on the Board of Directors and is the Chair of the Audit Committee for Biora, Inc. (BIOR) and she serves on the Board of Directors of Codagenix Inc. Ms. Howe earned her Bachelor of Arts in Accounting from San Diego State University and brings more than 20 years of significant strategic, financial, and operational experience, with an emphasis on capital strategy, corporate finance, treasury management, global infrastructure, and operational excellence in the life sciences industry.